Examples of 'omalizumab' in a sentence
Meaning of "omalizumab"
omalizumab (noun): a medication used to treat moderate to severe asthma and chronic hives
Show more definitions
- A monoclonal antibody used mainly in allergy-related asthma therapy with the purpose of reducing allergic hypersensitivity.
How to use "omalizumab" in a sentence
Basic
Advanced
omalizumab
Omalizumab is excreted in breast milk in cynomolgus monkeys.
It is unknown whether omalizumab is excreted in human milk.
There are no human fertility data for omalizumab.
Consider omalizumab for patients with allergies.
Xolair contains the active substance omalizumab.
Omalizumab is a recombinant humanized monoclonal antibody against IgE.
It is not known whether omalizumab is excreted in human breast milk.
Omalizumab crosses the placental barrier.
Xolair is a medicine that contains the active substance omalizumab.
Omalizumab is a medicine called an IgE blocker.
Formal carcinogenicity studies have not been conducted with omalizumab.
Omalizumab works by helping to block IgE.
The active substance is omalizumab.
Omalizumab aids simultaneous desensitization to several food allergies.
The general pharmacokinetic characteristics of omalizumab are similar in these populations.
See also
Omalizumab is safer than other treatments.
There are limited data from the use of omalizumab in pregnant women.
Omalizumab binds to IgE and lowers free IgE levels.
There are no adequate data from the use of omalizumab in pregnant women.
Omalizumab helps by blocking IgE.
The data suggest that a causal relationship between omalizumab therapy and malignancy is unlikely.
Omalizumab has been shown to reduce the number of asthma exacerbations.
You may not see immediate improvement in your asthma after omalizumab treatment begins.
Omalizumab is also effective for the treatment of allergic rhinoconjunctivitis.
The active substance of Xolair is omalizumab.
The pharmacokinetics of omalizumab have been studied in patients with allergic asthma.
But now a new threat associated with Omalizumab has emerged.
Omalizumab or placebo administered.
A history of anaphylaxis unrelated to omalizumab may be a risk factor for anaphylaxis following Xolair administration.
Omalizumab may also be useful in those with poorly controlled allergic asthma.
In one embodiment, the antibody is omalizumab.
Antibodies to omalizumab were detected in some monkeys following repeated subcutaneous or intravenous administration.
There is limited clinical experience in re-treatment of patients with omalizumab.
Omalizumab has been shown to reduce the number of asthma attacks in these patients.
Because his IgE levels were high, omalizumab was also administered.
Omalizumab crosses the placental barrier and the potential for harm to the foetus is unknown.
Therefore, indiscriminate blocking of IgE-receptor interaction with omalizumab may have unforeseen risks.
The pharmacokinetics of omalizumab have been studied in adult and adolescent patients with allergic asthma.
The latter mechanism was, however, not found in clinical trials performed with Omalizumab.
Omalizumab is not currently approved or indicated for CSU.
Finally, treatment with Omalizumab may prove to be costly.
Omalizumab for treatment of Food Allergies.
If you are allergic ( hypersensitive ) to omalizumab or any of the other ingredients of Xolair.
Omalizumab should not be given during breast-feeding.
Treatment of atopic subjects with omalizumab resulted in a marked down-regulation of Fc RI receptors on basophils.
Omalizumab is a man-made protein that is similar to natural proteins produced by the body.
The significant improvements observed with omalizumab were sustained throughout the treatment period up to Week 24.
Omalizumab blocks the activity of IgE, an immune system molecule central to the allergic response.
What Xolair contains - The active substance is omalizumab.
In vitro, omalizumab forms complexes of limited size with IgE.
